Literature DB >> 32949609

Long-term Outcomes After Pulmonary Endarterectomy in 499 Patients Over a 20-Year Period.

Shunsuke Miyahara1, Tom Alexander Schröder1, Heinrike Wilkens2, Irem Karliova1, Frank Langer1, Takashi Kunihara3, Hans-Joachim Schäfers4.   

Abstract

BACKGROUND: Pulmonary endarterectomy (PEA) is a curative treatment for chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary hypertension (PH) after PEA is not uncommon, and its impact on long-term outcomes is poorly understood. We investigated the effects of residual PH on current long-term survival and on postoperative status.
METHODS: Data of 499 consecutive patients who underwent PEA between December 1995 and December 2014 were analyzed retrospectively. Kaplan-Meier survival analysis was used to estimate the survival rates with the 95% confidence interval.
RESULTS: Overall survival at 5, 10, and 15 years postoperatively was 84.8% ± 1.9%, 77.1% ± 2.7%, and 59.2% ± 5.3%, respectively. Survival after discharge at 5, 10, and 15 years was 93.9% ± 1.5%, 85.4% ± 2.6%, and 65.6% ± 5.8%, respectively. Of all, 166 patients had residual PH immediately after PEA and a poorer prognosis regarding freedom from CTEPH-related death. CTEPH-related survival at 10 years in patients with normal pulmonary artery pressure vs residual PH was 89.0% ± 2.7% vs 67.9% ± 4.7%, respectively (P < .001). There was a trend to CTEPH-related survival after discharge being affected by residual PH (P = .092). At follow-up, patients with residual PH had worse exercise tolerance (P < .001) and symptoms (P < .001) compared with those with normal pulmonary artery pressure. The probability of developing PH over time was 41.9% at 15 years.
CONCLUSIONS: Survival after hospital discharge is excellent for patients undergoing PEA. Postoperative PH is associated with more symptoms and poorer functional capacity. Patients who have clinically relevant postoperative PH should be monitored closely and may be candidates for additional medical therapy.
Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32949609     DOI: 10.1016/j.athoracsur.2020.06.122

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Long-term outcomes after pulmonary endarterectomy.

Authors:  Fabio Dardi; Alessandra Manes; Daniele Guarino; Sofia Martin Suarez; Antonio Loforte; Mariangela Rotunno; Davide Pacini; Nazzareno Galiѐ; Massimiliano Palazzini
Journal:  Ann Cardiothorac Surg       Date:  2022-03

2.  Association of residual pulmonary hypertension with survival after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.

Authors:  Janica Kallonen; Kasper Korsholm; Fredrik Bredin; Matthias Corbascio; Mads Jønsson Andersen; Lars Bo Ilkjær; Søren Mellemkjær; Ulrik Sartipy
Journal:  Pulm Circ       Date:  2022-05-27       Impact factor: 2.886

3.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

4.  Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic.

Authors:  Pavel Jansa; David Ambrož; Matyáš Kuhn; Vladimír Dytrych; Michael Aschermann; Vladimír Černý; Virginie Gressin; Samuel Heller; Jan Kunstýř; Michal Širanec; Ci Song; Aleš Linhart; Jaroslav Lindner; Audrey Muller
Journal:  Pulm Circ       Date:  2022-03-28       Impact factor: 2.886

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.